RECENT WORK
Recent Work
Our research activities are mainly in the areas of nucleic acid biochemistry, protein biochemistry, peptide/protein chemistry, bioanalytical chemistry, chemical biology, and bioengineering. Our research aim is to develop next-generation platform for disease diagnostics and therapy. To realize this aim, we are interested in playing with Nature's building blocks, peptide, protein, DNA and RNA.
PD-L1/PD-1 interaction
PD-L1 are constitutively expressed or overexpressed on different types of human tumor cells.
Since cancer cells use the PD-L1 to help them evade immune attack, inhibitors that target PD-L1 can block this binding and boost the immune response against cancer cells. Our group is interested in developing biosensors for PD-L1 detection.
COVID-19
We have discovered DNA aptamers which can universally inhibit interactions between human ACE2 and spike proteins of various SARS-CoV-2 variants. We also reported the first anti-S2 aptamer.